Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.97 | N/A | +766.07% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.97 | N/A | +766.07% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the strong EPS results, highlighting their commitment to pipeline advancements. They maintained a cautious outlook without providing specific guidance.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
Neurocrine Biosciences reported a significant EPS beat, which contributed to a 6.72% increase in stock price. The strong performance indicates effective cost management and operational efficiency. However, the lack of revenue data and future guidance leaves some uncertainty for investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KRYSTAL BIOTECH INC